

Market Announcement

8 December 2022

CardieX Limited (ASX: CDX) – Suspension from Quotation

Description

The securities of CardieX Limited ('CDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding the finalisation of a material contract in relation to its clinical trial revenue.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance (Sydney)



Lisa Banh
Senior Advisor
Listings Compliance (Sydney)
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

By email: companies_sydney@asx.com.au; tradinghaltsydney@asx.com.au

8 December 2022

Dear Lisa,

Request for Voluntary Suspension on Securities of CardieX Limited (ASX:CDX) (CardieX or the Company)

Pursuant to ASX Listing Rule 17.2, pending an announcement regarding a material contract in relation to its clinical trial revenue, CardieX formally applies for a voluntary suspension to be put in place immediately.

The suspension is requested to be in place until the earlier of commencement of trade Friday, 9 December 2022 or when that announcement is released to the market.

The Company is not aware of any reason why the Company's request for a voluntary suspension should not be granted.

Yours sincerely,

A handwritten signature in blue ink, appearing to read "Jarrod White", written over a light blue circular stamp.

Jarrod White
Director
CardieX Limited

CardieX Limited
ACN 113 252 234
Suite 301/55 Lime Street
Sydney NSW 2000